Literature DB >> 2786387

DR4 prevalence related to the age at disease onset in female patients with rheumatoid arthritis.

J M Hazes1, B A Dijkmans, J M Hoevers, J J Janson, R R de Vries, J P Vandenbroucke, A Cats.   

Abstract

The prevalence of HLA-DR4 in relation to age at disease onset was calculated in 226 consecutive female patients with definite or classical rheumatoid arthritis (RA). A slight increase in the prevalence of DR4 with age at RA onset was found. This appeared to be due to the low percentage of rheumatoid factor (RF) positivity in the youngest age groups; the DR4 prevalence in the RF positive patients was constant for all decades--that is, approximately 60%. A previously reported declining trend of DR4 prevalence in women with RA in relation to age of RA onset may be due to the disease heterogeneity of the patients included in that study.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786387      PMCID: PMC1003771          DOI: 10.1136/ard.48.5.406

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Simultaneous detection of two cell populations by two-colour fluorescence and application to the recognition of B-cell determinants.

Authors:  J J van Rood; A van Leeuwen; J S Ploem
Journal:  Nature       Date:  1976-08-26       Impact factor: 49.962

3.  Epidemiological study of HLA and GM in rheumatoid arthritis and related symptoms in an open Dutch population.

Authors:  B M de Jongh; L K van Romunde; H A Valkenburg; G G de Lange; J J van Rood
Journal:  Ann Rheum Dis       Date:  1984-08       Impact factor: 19.103

4.  An immunogenetic study of older age onset rheumatoid arthritis.

Authors:  R Terkeltaub; F Décary; J Esdaile
Journal:  J Rheumatol       Date:  1984-04       Impact factor: 4.666

5.  HLA antigens and seronegative rheumatoid arthritis.

Authors:  T Bardin; L Legrand; B Naveau; A Marcelli-Barge; N Debeyre; G M Lathrop; J C Poirier; M Schmid; A Ryckewaert; A Dryll
Journal:  Ann Rheum Dis       Date:  1985-01       Impact factor: 19.103

6.  The association between rheumatoid arthritis and the HLA antigen DR4.

Authors:  J T Gran; G Husby; E Thorsby
Journal:  Ann Rheum Dis       Date:  1983-06       Impact factor: 19.103

7.  Association of HLA-DR4/Dw4 and DR2/Dw2 with radiologic changes in a prospective study of patients with rheumatoid arthritis. Preferential relationship with HLA-Dw rather than HLA-DR specificities.

Authors:  A Young; D Jaraquemada; J Awad; H Festenstein; M Corbett; F C Hay; I M Roitt
Journal:  Arthritis Rheum       Date:  1984-01

8.  HLA antigen associations with extra-articular rheumatoid arthritis.

Authors:  W Ollier; P J Venables; P A Mumford; R N Maini; J Awad; D Jaraquemada; J D'Amaro; H Festenstein
Journal:  Tissue Antigens       Date:  1984-11

9.  Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs.

Authors:  G S Panayi; P Wooley; J R Batchelor
Journal:  Br Med J       Date:  1978-11-11

10.  Association of HLA-DRw4 with rheumatoid arthritis in black and white patients.

Authors:  R W Karr; G E Rodey; T Lee; B D Schwartz
Journal:  Arthritis Rheum       Date:  1980-11
View more
  3 in total

Review 1.  Rheumatoid arthritis in the elderly. Prevalence and optimal management.

Authors:  D van Schaardenburg
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

Review 2.  Management issues with elderly-onset rheumatoid arthritis: an update.

Authors:  Ignazio Olivieri; Carlo Palazzi; Giovanni Peruz; Angela Padula
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Genetic risk score predicting risk of rheumatoid arthritis phenotypes and age of symptom onset.

Authors:  Lori B Chibnik; Brendan T Keenan; Jing Cui; Katherine P Liao; Karen H Costenbader; Robert M Plenge; Elizabeth W Karlson
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.